#Germany #Fremont #Alamar Biosciences #DZNE #Proteomic Study

Alamar Biosciences and DZNE Team Up for Groundbreaking Proteomic Profiling Study

In an innovative step towards understanding neurodegenerative diseases and the aging process, Alamar Biosciences has officially announced a strategic collaboration with the German Center for Neurodegenerative Diseases (DZNE). This partnership aims to leverage the company's cutting-edge proteomics technology to significantly enhance the early detection of diseases through comprehensive profiling in their Rhine study cohort, one of the most extensive and advanced longitudinal studies of aging worldwide.

The project's focus is to implement Alamar’s highly sensitive CNS panel NULISAseq™ 120 and the inflammatory panel 250 to analyze plasma samples from a cohort of 23,000 individuals. This initiative is poised to fast-track the discovery of biomarkers that can lead to a deeper understanding of healthy aging and neurodegeneration.

Professor Monique Breteler, the Director of Population Health Sciences at DZNE and the leading researcher of the Rhine study, emphasizes the importance of sophisticated technologies and well-characterized cohorts in deciphering aging and dementia. She notes, “Integrating Alamar’s multiplex panels into our research opens new avenues for decoding the molecular signatures of brain aging.”

What is the Rhine Study?

The Rhine study is a large-scale population-based cohort study designed by DZNE, focusing on investigating the determinants of healthy aging and the progression of neurodegenerative diseases spanning a lifetime. To achieve this, the study collects and harmonizes detailed clinical, imaging, genetic, and lifestyle data to gain comprehensive insights into the aging brain.

Alamar's CNS panel, NULISAseq 120, is set to revolutionize the way researchers assess hundreds of brain-related proteins using minimal blood samples with exceptional sensitivity and specificity. Of particular note is the panel's ability to distinguish phosphorylated tau protein from the brain from total phosphorylated tau protein present in plasma, marking a transformative advancement in the early detection and risk stratification of neurodegenerative conditions, including Alzheimer’s disease.

Additionally, the inflammatory panel NULISAseq 250 offers one of the most detailed and sensitive profiles of immune-related proteins involved in aging and neuroinflammation linked to neurodegenerative diseases.

The proteomic data generated through this collaboration will be integrated with extensive clinical, demographic, and imaging datasets from the Rhine study. This will allow researchers to track changes in protein levels over time, identify early biomarkers, and support the development of precise diagnostics and targeted therapies.

Dr. Yuling Luo, Founder, Chairman, and CEO of Alamar Biosciences, stated, “This partnership marks a significant step forward in aging and dementia research. With the unparalleled sensitivity of the NULISA panels and the depth of the Rhine study at DZNE, we can discover novel protein biomarkers revealing trajectories of cognitive health and disease progression in aging populations.”

This collaboration reflects a shared commitment to scientific rigor, inclusivity, and innovation in the field of neurodegenerative disease research. By capturing diverse trajectories of aging within a thoroughly characterized population, Alamar and DZNE aim to promote earlier diagnosis, enhance prognostic capabilities, and discover new therapeutic pathways for age-related brain disorders.

About DZNE's Rhine Study

DZNE's Rhine Study is an ambitious population cohort tracking thousands of individuals over decades to uncover the determinants of healthy aging and neurodegeneration. Detailed clinical, imaging, and lifestyle data along with genetic information are collected and harmonized to offer deeper insights into the aging brain. To learn more about DZNE, visit www.dzne.de/en/ or explore the Rhine Study at www.rheinland-studie.de/en/.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private life sciences company dedicated to advancing precision proteomics for early disease detection. Its proprietary platform, NULISA, along with the ARGO HT system, seamlessly integrates the latest advancements in genomics to achieve single-digit attomolar sensitivity, significantly surpassing current best-in-class protein detection technologies. More information can be found at alamarbio.com.